ZS Pharma (FRA:0ZS) 12-1 Month Momentum % : N/A% (As of May. 07, 2024)

View and export this data going back to . Start your Free Trial

What is ZS Pharma 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-07), ZS Pharma's 12-1 Month Momentum % is N/A%.

The industry rank for ZS Pharma's 12-1 Month Momentum % or its related term are showing as below:

FRA:0ZS's 12-1 Month Momentum % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -6.33
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of ZS Pharma's 12-1 Month Momentum %

For the Drug Manufacturers - General subindustry, ZS Pharma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZS Pharma's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZS Pharma's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where ZS Pharma's 12-1 Month Momentum % falls into.

ZS Pharma (FRA:0ZS) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZS Pharma (FRA:0ZS) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

ZS Pharma 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of ZS Pharma's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

ZS Pharma (FRA:0ZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZS Pharma Inc (FRA:0ZS) » Definitions » 12-1 Month Momentum %

Traded in Other Exchanges

N/A

Address

Website

http://www.zspharma.com

ZS Pharma Inc was incorporated in Delaware in February 2008. The Company is a biopharmaceutical company engaged in the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It was initially engaged in the development of ZS-9, its product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood (greater than 5.0 mEq/L) and is a life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. ZS-9 is currently in Phase 3 clinical development. ZS-9 is a therapy to treat hyperkalemia, regardless of the underlying cause, and allows patients to benefit from the cardio-renal protective effect of RAAS therapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address CKD, HF and metabolic diseases. It faces competition from many pharmaceutical and biotechnology companies that are researching and selling products to treat CKD, HF and metabolic diseases. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

ZS Pharma (FRA:0ZS) Headlines

No Headlines